Related Experiment Video
Updated: Jun 10, 2026
Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
[Resistance/sensitivity in vitro in ovarian cancer patients]
I Sedláková1, J Tosner, A Rezác
1Porodnickiá a gynekologická klinika LF UK a FN, Hradec Králové. sedlakiva@seznam.cz
Objective:
To assay resistance/sensitivity by MTT test in solid tumor or ascitic fluid in ovarian cancer patients.
Design:
Prospective study.
Setting:
Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.
Methods:
MTT - (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) chemosensitivity assay was performed in 32 samples of ovarian cancer tissue and 26 samples of ascitic fluid in ovarian cancer patients. We studied the in vitro drug resistance profiles of ovarian cancer specimens exposed to cisplatin, carboplatin, paclitaxel, topotecan, gemcitabin, etoposid.
Results:
The highest frequency of resistance in vitro occured for etoposid, gemcitabin and paclitaxel and the most effective chemotherapeutical agents in vitro were cisplatinum and topotecan. Cisplatin had the lowest incidence of drug resistance in vitro than carboplatin.
Conclusion:
Resistance/sensitivity assay would improve the treatment and prognosis of ovarian cancer patients.
